Plasmacure Health-tech Company Secures €6M In Series A Funding

The investment was led by Venture Medical, a U.S. healthcare firm with over 15 years of experience in wound care.

Venture Medical will also support U.S. regulatory approval and reimbursement efforts, with a total go-to-market investment expected to exceed $10 million (around €8.5 million).

The funding round also included Dutch health insurer Coöperatie VGZ, impact investor Noaber, and Stichting Triade, along with existing investors EIC Fund and Oost NL.

Read Also - Netherlands’ GeniusTravel Secures €2M for AI Holiday App

Plasmacure is the developer of PLASOMA, a cold plasma system designed to help heal complex wounds like diabetic foot ulcers, venous leg ulcers, and pressure sores.

This funding will help Plasmacure expand globally and promote PLASOMA as a next-generation solution for advanced wound care.

“We are deeply motivated by the needs of the millions living with hard-to-heal wounds,” says Bjorn Sprengers, CEO of Plasmacure. “With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide. Our vision is to transform wound care; improve outcomes and give patients back their mobility, dignity, and freedom. With PLASOMA, we aim to set a new global standard in the treatment of complex wounds.”

With a growing elderly population and rising diabetes cases, about 5% of older adults suffer from complex wounds, which can lower quality of life and may even lead to amputations. Existing treatments often fall short and account for 2–4% of total healthcare costs.

Plasmacure, led by Bjorn Sprengers, has developed a breakthrough solution called PLASOMA—a cold plasma system that helps heal difficult wounds. Studies show that PLASOMA can close wounds up to 2.5 times more effectively than standard treatments.

PLASOMA works by creating cold plasma, a powerful antimicrobial gas made by energising molecules. This gas kills even antibiotic-resistant bacteria, boosts blood flow, and supports cell growth.

The system uses a pulser device that sends electric pulses to a disposable pad, producing cold plasma directly on the wound. This starts several healing processes at once, helping wounds recover faster and improving patient outcomes.

“We see PLASOMA as a transformative technology that redefines what’s possible in wound healing. By investing in Plasmacure and supporting its U.S. rollout, we are enabling clinicians to offer next-generation care that is both innovative and accessible,” says John Schroeder, CEO of Venture Medical.

About Plasmacure

Founded in 2013, Plasmacure aims to transform wound care for people with hard-to-heal wounds. Its cold plasma system, PLASOMA, is proven to heal complex wounds 2.5 times more effectively than traditional treatments. Easy to use and CE-marked, PLASOMA helps reduce costs, improve patient outcomes, and restore mobility and dignity.